(RYTM) Rhythm Pharmaceuticals - Ratings and Ratios

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company specializing in rare neuroendocrine disorders. Its flagship product, IMCIVREE (setmelanotide), is a melanocortin-4 receptor agonist approved for treating obesity in conditions like POMC, PCSK1, LEPR deficiency, Bardet-Biedl, and Alström syndromes. The drug is in Phase 3 trials for additional indications, including steroid receptor coactivator 1 deficiency, SH2B1 deficiency, MC4 receptor deficiency, and other MC4R-related disorders. The company has established partnerships with LG Chem, Ipsen Pharma, Camurus, and RareStone Group, and collaborates with Axovia Therapeutics on Bardet-Biedl syndrome research. Originally named Rhythm Metabolic, Inc., the company rebranded in 2015 and operates from its Boston headquarters since 2008.

RYTMs stock shows a last price of $63.76, with a 20-day average volume of 667,528 shares. Technical indicators reveal a bullish trend, as the SMA 20 ($57.42) surpasses the SMA 50 ($55.03) and SMA 200 ($53.57). The ATR of 3.49 signals moderate volatility. Fundamentally, the companys market cap is $3.9 billion, with a P/B ratio of 179.64 and P/S of 30.00, reflecting high valuations. Over the next three months, expect RYTM to maintain its upward trajectory, potentially reaching $70-$75, driven by positive clinical trial progress and strong revenue growth from IMCIVREE sales.